Sanofi S.A., FR0000120578

Sanofi stock steadies near EUR 74 as earnings and pipeline weigh

Published on 09/22/2026 at 11:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sanofi stock traded at EUR 74.59 on September 21, 2026, down 10.48 percent year to date. July revenue rose 16.0 percent to USD 13.36 billion.

Modern pharmaceutical sterile fill-and-finish manufacturing facility interior with glass vial-filling machines and cleanroom workers in white suits — Sanofi FR0000120578 photorealistic sterile fill-and-finish facility with vial-filling machines and cleanroom workers, Illustration mit AI erstellt.

Sanofi (ISIN FR0000120578) closed at EUR 74.59 on Euronext Paris on September 21, 2026, while the stock was down 10.48 percent year to date. The latest market data place the shares 18.2 percent below their 52-week high of EUR 91.15 and only 4.7 percent above the 52-week low of EUR 71.25.

Cheplapharm deal adds a concrete catalyst

Sanofi agreed on September 15, 2026, to transfer a portfolio of 20 mature medicines and three manufacturing sites to Cheplapharm in exchange for a 26.4 percent stake in the privately held company, according to Bolsamania.

The transaction covers facilities in Hungary, Singapore and France and includes enoxaparin products marketed under the Lovenox and Clexane names, according to the same September 15, 2026 report from Bolsamania. The structure gives Sanofi an equity interest rather than a simple cash exit, so the strategic value depends on how effectively the new partnership develops the transferred assets.

July results show higher revenue

For the quarter reported on July 30, 2026, Sanofi posted earnings per share of USD 2.41 and revenue of USD 13.36 billion, according to MarketBeat. Revenue increased 16.0 percent from the same quarter of the prior year, while EPS declined from USD 3.24, making the comparison more complex than the top-line growth alone suggests.

The same July 30, 2026 report listed a net margin of 8.66 percent and return on equity of 14.19 percent. For investors, the key issue is therefore the conversion of revenue growth into earnings, particularly as Sanofi continues to balance specialty medicines, vaccines and mature products.

Consensus remains cautious

Sixteen research firms carried an average Hold recommendation on September 22, 2026, with an average twelve-month price objective of USD 49.50, according to MarketBeat. The coverage included 1 sell, 10 hold, 3 buy and 2 strong buy ratings, while Morgan Stanley had set a USD 49.00 target on July 8, 2026.

The Paris-listed shares ended September 21, 2026, at EUR 74.59, compared with the EUR 91.15 52-week high and EUR 71.25 low. That 19.0 percentage-point spread between the year-to-date decline and the distance from the yearly high frames the stock as a valuation and execution story rather than a simple earnings-growth trade.

Sanofi stock stays near yearly low

Sanofi stock closed at EUR 74.59 on Euronext Paris on September 21, 2026. The same dated market snapshot recorded a 52-week range of EUR 71.25 to EUR 91.15 and a year-to-date performance of minus 10.48 percent.